Ownership history in XTX Topco Ltd Β· 9 quarters on record
This page tracks every 13F SEC filing in which XTX Topco Ltd reported a position in TG THERAPEUTICS INC (TGTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π XTX Topco Ltd outperformed the S&P 500 by +159.3% annually on this TGTX position. Timing score: 50% (4/8 decisions correct). Average cost basis: $20.04. Maximum drawdown during holding period: β66.3%.
π₯ Exceptional β beat the S&P 500 by 159.3% per year on this position.
8 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
4 of 8 add/trim decisions correct
Best entry: $4.25 (2022 Q2) Β· Worst: $39.43 (2025 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 4 trims. Bought during 2 of 2 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.09% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size